Finished product reference
Calcium Dobesilate
Tablet · Oral · 500 mg
- List code
- 8927
- Pharmacologic class
- Vasoprotective agent (angioprotector)
What it is and how it works
Calcium dobesilate reduces capillary hyperpermeability and increases capillary resistance, decreases blood viscosity and platelet aggregation, and has antioxidant effects. These actions are thought to improve microcirculation and reduce oedema.
Indications
Diabetic retinopathy and other microangiopathies; symptoms of chronic venous insufficiency (e.g. pain, heaviness, oedema) and adjunctive treatment of haemorrhoidal symptoms.
Dosage and administration (summary)
Adults: usually 500 mg orally one to three times daily with meals, depending on the indication and severity.
Contraindications
Hypersensitivity to calcium dobesilate.
Warnings and precautions
Agranulocytosis has been reported rarely; patients should report fever, sore throat or mouth ulcers immediately and treatment should be stopped and a blood count performed. Dose reduction may be needed in severe renal impairment. May interfere with some laboratory assays (e.g. creatinine measured by enzymatic methods).
Pregnancy
Avoid in pregnancy, particularly the first trimester, as data are limited.
Storage and supply
Store below 30 °C, protected from moisture.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.